Coming Soon
Please return to take advantage of this benefit starting January 1st, 2024

Introducing Galleri®, the first-of-its-kind multi-cancer early detection test that looks for a signal shared by 50+ types of cancer with a single blood test.1

Who is eligible?

The Galleri test is available at no cost to employees enrolled in an Okta medical plan and covered spouses/domestic partners that also meet the following criteria.

Eligibility requirements

  • 50 years or older 
  • 40-49 with risk factors
  • Not currently pregnant or undergoing cancer treatment 
  • 40-49 years old AND at least one of the following risk factors:
    • Cancer survivor who has completed treatment within the last three years*
    • Currently smokes or quit smoking within the last 10 years
    • Diagnosis of cirrhosis or chronic Hepatitis B or C infection
    • Infection with certain strains of HPV (e.g. HPV 16 or 18)
    • Known hereditary cancer syndrome
      • Confirmation or documentation of a gene mutation associated with increased cancer risk (e.g., Li-Fraumeni syndrome, Hereditary Breast and Ovarian Cancer syndrome [BRCA1/2], Lynch syndrome, CHEK2).
  • 40-49 years old AND at least two of the following risk factors:
    • Documented genetic predisposition (germline variant)
    • First degree relative with cancer**
    • History of HIV infection
    • Current use of immunosuppressive therapies after organ transplantation
    • Diabetes
    • BMI:
      • Female ≥ 30
      • Male ≥ 35

*excludes basal or squamous cell carcinoma of the skin
**excludes basal or squamous cell carcinoma of the skin and/or the second cancer is not a recurrence or metastasis
Black couple sitting at their kitchen table writing on a notepad with a cup of coffee and a tablet on the table in front of them

What is the Galleri test?

Patient testimonial: Roger

Cancer Signal Detected

Roger testimonial

  1. Klein EA, Richards D, Cohn A, et al. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set.Ann Oncol. 2021;32(9):1167-77. DOI: